Better labelling of excipients for safe use of medicines
Updated annex to excipient guidelines has new safety advice for 15 excipients
The European Medicines Agency (EMA) and the European Commission have updated the annex to the European Commission guideline on excipients in the labelling and package leaflet of medicinal products for human use.
Excipients refer to everything in a medicine other than the active substance. While most excipients are considered inactive, some can have a known action or effect in certain circumstances. These must be declared in the labelling of the medicine for its safe use.
The updated annex contains all excipients that must be declared in a medicine’s labelling and package leaflet and their agreed safety warnings. The main aim of this update is to take into account safety concerns which are not currently addressed in the existing annex to the guideline. It also pays specific attention to, for example, the safety of these excipients when used in children or pregnant women.
The updated annex includes five new excipients and new safety warnings for ten existing excipients. The new safety information will help patients and healthcare professionals make more conscious decisions about the medicines they take and prescribe.
The updated annex takes account of the comments received for each excipient during public consultations and is published, in all European Union languages, along with scientific reports.
The revised annex applies to both centrally and nationally authorised products. For new marketing authorisation applications the revised annex will be effective from its day of publication and applicants must implement the information in the labelling. For already authorised medicines, marketing authorisation holders should use the first opportunity to implement the wording in compliance with the revised annex. For medicines with no foreseeable regulatory submissions, marketing authorisation holders should submit a type IB variation within three years after the publication of the revised annex.
- Excipients labelling
- Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’
- European Commission guideline on 'Excipients in the label and package leaflet ofmedicinal products for human use'
- European Commission
Latest News from
EU agrees to make parcel delivery more affordable15/12/2017 13:20:00
EU negotiators reached a provisional agreement last night to make prices for cross-border parcel delivery services more transparent & affordable and to increase regulatory oversight of the EU parcel market.
EC welcomes agreement on key legislation to tackle climate change15/12/2017 12:20:00
The European Parliament and Council have reached a provisional agreement on a key legislative proposal for implementing the EU's 2030 climate objectives – on accounting of emissions from land use, land use change and forestry (LULUCF).
Joint Declaration on the EU's legislative priorities for 2018-201915/12/2017 11:20:00
European Commission President Jean-Claude Juncker has signed the new Joint Declaration on the EU's legislative priorities for 2018-2019.
EU farm policy rules to be further simplified14/12/2017 16:25:00
A raft of changes due to come into force on 1 January 2018 continue the drive towards a simpler, more modern Common Agricultural Policy (CAP).